EMPATHY: Effective Management of Pain Along the Treatment of Hematologic Malignancy
January 31, 2023
Jaanuary 31, 2024
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by The American Society of Hematology (ASH), in collaboration with The France Foundation.
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hours
- Physician Assistants — 1.0 AAPA Category 1 CME credits
All other healthcare professionals completing this course will be issued a statement of participation.
The target audience for this initiative includes hematologists/oncologists, primary care physicians, physician assistants, nurse practitioners, pharmacists, and care team members involved in the management of patients with hematologic malignancies.
The Opioid Analgesic REMS is designed to ensure that the benefits of opioid analgesics outweigh the risks. The goal of this actvity is to address this need by providing education to the healthcare team on the treatment and monitoring of patients who are manage patients with hematologic malignancies.
This activity will also provide information about the risks of opioids and use of other therapies, which is intended to assist HCPs in reducing adverse outcomes of addiction/substance use disorder, unintentional overdose, and death resulting from inappropriate prescribing and misuse of opioid analgesics.
Upon completion of this activity, participants should be better able to:
- Understanding the fundamental concepts of pain management, including definitions and mechanisms of pain
- Assessing patients with pain and identifying potential risk factors for opioid use disorder
- Utilizing the range of therapeutic options for managing pain, including non-pharmacologic approaches and pharmacologic (nonopioid and opioid analgesics) therapies
- Integrating opioid analgesics into a pain treatment plan individualized to meet the needs of the patient
- Managing patients on opioid analgesics safely and effectively in the acute and chronic pain settings, including initiating therapy, titrating, and discontinuing use of opioid analgesics, if appropriate and necessary
- Counseling patients and caregivers on the safe use of opioid analgesics, including proper storage and disposal
- Counseling patients and caregivers about the use of naloxone for opioid overdose
- Referring patients to a pain specialist, as appropriate
- Utilizing the fundamental elements of addiction medicine (ie, diagnosis, prevention, evaluation, treatment, and recovery of patients with opioid use disorder)
- Identifying and managing the care of patients with opioid use disorder
- The current information about safe opioid practices and current federal and state regulations, national guidelines, and professional organization and medical specialty guidelines on treating pain and prescribing opioids
- The use of naloxone and the importance of its availability for use by patients and caregivers in the community and home.
Paige Moriah Farinholt, MD
Medicine-Hematology & Oncology
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Thomas LeBlanc, MD, MA
Associate Professor of Population Health Sciences
Department of Population Health Sciences
Associate Professor of Medicine, With Tenure, Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine
Duke University School of Medicine
Durham, North Carolina
The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
- IPE Competencies
- Roles/ Responsibilities
- Interprofessional Communication
ASH designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid through November 30, 2023. PAs should only claim credit commensurate with the extent of their participation.
The France Foundation designates this activity for 1.0 contact hours.
All other health care professionals completing this course will be issued a statement of participation.
Disclosures of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ASH and The France Foundation (TFF) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. ASH and TFF resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, ASH and TFF seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. ASH and TFF are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.
Paige Moriah Farinholt, MD, has no relevant financial disclosures.
- Thomas LeBlanc, MD, MA
- Non-CE Consulting: AbbVie, Agios/Servier, AstraZeneca, Astellas, BlueNote, BMS/Celgene, Flatiron, GlaxoSmithKline, Genentech, Novartis, Pfizer
- Non-CE Speakers Bureau: AbbVie, Agios/Servier, BMS/Celgene
- Contract Research: BMS, Deverra Therapeutics, Jazz
- Royalties: UpToDate, Inc.
Charles Clayton, ASH Staff, has no relevant financial disclosures.
Janis Vajdos, MS, TFF Staff, has no relevant financial disclosures.
Heather Tarbox, MPH, TFF Staff, has no relevant financial disclosures.
Patrick Harty, PhD, TFF Content Reviewer, has no relevant financial disclosures.
Instructions for Participation and Credit
There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the activity and the embedded questions, and completing the evaluation form.
- Credit fulfillment
- If you are requesting AMA credits, ANCC credits, AAPA credits, or a certificate of participation, your certificate will be available for download.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
ASH and TFF require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. ASH and TFF do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
The American Society of Hematology and The France Foundation present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ASH, TFF, and the commercial supporter(s) assume no liability for the information herein.
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or firstname.lastname@example.org.